For the drug treatment of patients with advanced NSCLC: (1) First-line drug therapy. The platinum-containing two-drug regimen is the standard first-line chemotherapy regimen, which can be combined with vascular endothelial inhibitors on top of chemotherapy; patients with EGFR gene-sensitive mutations or positive ALK fusion genes can be targeted with targeted drug therapy. For patients who achieve disease control (complete remission, partial remission and stability) with first-line therapy, maintenance therapy can be selected. The drugs currently supported by evidence-based medical evidence for maintenance therapy are pemetrexed (non-squamous cancer) and gemcitabine; the drugs supported by evidence-based medical evidence for switching maintenance therapy are pemetrexed (non-squamous cancer), and for patients with EGFR gene-sensitive mutations, epidermal growth factor receptor tyrosine kinase inhibitors can be selected for maintenance therapy. (2) Second-line drug therapy. The drugs available for second-line treatment include doxorubicin, pemetrexed and EGFR-TKI. for patients with EGFR gene sensitive mutation, if EGFR-TKI is not applied in first-line and maintenance treatment, EGFR-TKI should be applied in second-line treatment as a priority; for patients with negative EGFR gene sensitive mutation, chemotherapy should be considered as a priority. (3) Third-line drug therapy. EGFR-TKI can be chosen or participate in clinical trials. In terms of chemotherapy, the patient’s current situation should be prioritized if they are negative for EGFR gene sensitive mutation. For lung cancer treatment, the principle of combining multidisciplinary comprehensive treatment and individualized treatment should be adopted, that is, to adopt a multidisciplinary comprehensive treatment model according to the patient’s body condition, pathological histological type and molecular typing of tumor, invasion scope and development trend, and to apply surgery, chemotherapy, radiotherapy and molecular targeted therapy in a planned and rational manner, so as to maximize the survival time of patients, improve The aim is to maximize survival time, improve survival rate, control tumor progression and improve patients’ quality of life. If the tumor recurs after second-line chemotherapy, don’t just focus on chemotherapy, whether radiotherapy and molecular targeted therapy are feasible or not, you need to be evaluated by the doctor concerned, and there are also tumor biotherapy (immunotherapy) and Chinese medicine treatment.